QGEN Nov 2024 40.000 call
| Previous close | 7.00 |
| Open | 7.00 |
| Bid | 5.20 |
| Ask | 6.80 |
| Strike | 40.00 |
| Expiry date | 2024-11-15 |
| Day's range | 7.00 - 7.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 28 |
ZacksQIAGEN (QGEN) Advances Precision Medicine With New QIAseq Kit
QIAGEN (QGEN) launches the new QIAseq Multimodal DNA/RNA Lib Kit, facilitating multiomic studies and advancing precision medicine.
GlobeNewswireQIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improve gastrointestinal care
U.S. FDA clears QIAstat-Dx Gastrointestinal Panel 2 for use in clinical settings // New panel offers fast and accurate identification of up to 16 common gastrointestinal pathogens // Generates results in about one hour based on real-time PCR technology, easy access to Ct values and amplification curvesGermantown, Maryland, and Venlo, the Netherlands, June 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAstat-Dx Gastrointestinal
ZacksQIAGEN (QGEN) Develops Test for Research and CDx Application
QIAGEN's (QGEN) next-generation sequencing test aims to aid personalized medicine research in solid tumor types, including ovarian cancer, and improve decentralized testing capabilities.
